Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients

0 avis

Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients

Archive ouverte

Edité par CCSD ; Elsevier -

International audience. Cancer patients are considered highly vulnerable to the COVID-19 pandemic. However, delaying cancer-specific therapies could have a deleterious effect on survival. The potential suppressive effects of chemotherapies or cancer-related microenvironment raised the question on how cancer patients' immune system responds to SARS-CoV-2 virus.

Langue: en

Indexation

Consulter en ligne

Consulter le document

Suggestions

Du même auteur

COVID-19 patients display distinct SARS-CoV-2 specific T-cell responses according to disease severity

Archive ouverte | Kroemer, Marie | CCSD

International audience. Adaptive Immune responses generated by SARS-CoV-2 virus in convalescent patients according to disease severity remain poorly characterized. To this end, we designed a prospective study (NCT04...

FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study

Archive ouverte | Vienot, Angélique | CCSD

International audience

Safety, Immunogenicity, and 1-Year Efficacy of Universal Cancer Peptide–Based Vaccine in Patients With Refractory Advanced Non–Small-Cell Lung Cancer: A Phase Ib/Phase IIa De-Escalation Study. Quelle formation académique pour les nouvelles missions de pharmacie clinique à l’officine ? Exemple du bilan partagé de médication du sujet âgé

Archive ouverte | Adotévi, Olivier | CCSD

International audience. PURPOSE Universal cancer peptide–based vaccine (UCPVax) is a therapeutic vaccine composed of two highly selected helper peptides to induce CD4+ T helper-1 response directed against telomerase...

Chargement des enrichissements...